Idorsia's Fabry disease program flops a PhIII study, leaving its future unclear
A top program for Swiss biotech Idorsia faces a murky future after flunking a Phase III test.
Idorisa’s drug candidate for Fabry disease, known as lucerastat, did not achieve the primary endpoint in a 118-patient pivotal study, the biotech announced Monday morning. The company, releasing no data, says it plans to wait for interim results from an open-label extension before making a decision about the program, but admits that could take up to four years.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 120,500+ biopharma pros reading Endpoints daily — and it's free.